The FDA has removed semaglutide from its drug shortage list after the agency determined the current supply of the drug can ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Shares tumbled 21% to $52.22. Over the last year, the stock has surged more than 450%.

The massive crash came after the US Food and Drug Administration (FDA) website showed the end of the shortage of Novo Nordisk ...

The U.S. FDA announced Friday that it would refrain from penalizing makers of compounded versions of Novo Nordisk’s (NVO) weight loss/obesity drugs as supply conditions for the GLP-1s improve after an ...

After steel and aluminium, US President Donald Trump has set his sights on slapping 25 percent tariffs on semiconductors, ...

The FDA said Friday that the shortage of semaglutide, the main ingredient in Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy, ...

Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration has determined the shortage of Wegovy and Ozempic is resolved. “The ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply squeeze on Novo Nordisk’s diabetes and obesity counterpa | The FDA has ...

Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has determined the shortage of Wegovy® and Ozempic® is resolved. The FDA's assessment confirms the U.S. supply of these ...

The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...

Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of ...